Proactive Drug Monitoring Is Associated With Higher Persistence to Infliximab and Adalimumab Treatment and Lower Healthcare Utilization Compared With Reactive and Clinical Monitoring.

Syed, Nauroz; Tolaymat, Mazen; Brown, Sara A; Sivasailam, Barathi; Cross, Raymond K

Syed, Nauroz; Tolaymat, Mazen; Brown, Sara A; Sivasailam, Barathi; Cross, Raymond K.

Afiliação

Syed N; Department of Medicine, Division of Gastroenterology and Hepatology, Penn State Hershey College of Medicine, Hershey, Pennsylvania, USA.
Tolaymat M; Department of Medicine, Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Brown SA; Department of Medicine, Division of Gastroenterology and Hepatology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Sivasailam B; Department of Medicine, Division of Internal Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Cross RK; Department of Medicine, Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Crohns Colitis 360 ; 2(3): otaa050, 2020 Jul.

Article em En | MEDLINE | ID: mdl-32743546

Palavras-chave

adalimumab; infliximab; therapeutic drug monitoring

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Aspecto: Implementation_research Idioma: En Revista: Crohns Colitis 360 Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google